Venous Thrombosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Venous Thrombosis Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Venous Thrombosis; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Venous Thrombosis receives an overall strategic score of 56/100. The opportunity combines an unmet-need score of 64/100, competition score of 95/100 and market-attractiveness score of 83/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

The formation or presence of a blood clot (THROMBUS) within a vein.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Venous Thrombosis, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID 6bd8a101cb79410b949a0fc64c6fce2d and MeSH identifier D020246. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Heart Disease and Stroke Statistics—2021 Update

ICD-9 451.1, 451.2, 451.81, 451.9, 453.0, 453.1, 453.2, 453.3, 453.4, 453.5, 453.9; ICD-10 I80.1, I80.2, I80.3, I80.9, I82.0, I82.1, I82.2, I82.3, I82.4, I82.5, I82.9. 2018: Mortality—3230. Any-mention mortality—17 160. 2016: Hospital discharges—102 000 (principal diag- nosis), 602 000 (all-listed diagnoses). Venous Thromboembolism Incidence (See Charts 23-1 and 23-2) • VTE includes both PE and DVT. In 2016, there were an estimated ≈370 000 cases of PE (HCUP NIS Chart 23-1), ≈857 000 cases of DVT (HCUP NIS Chart 23-2), and ≈1 220 000 total VTE cases in the United States (US population was 323 million in 2016); these estimates used the all-listed diagno- ses hospitalization data and assumed that 30% of DVTs were treated in an outpatient setting. • In 2016, there were 1 001 000 physician office visits and 211 000 ED visits with a principal diag- nosis of DVT (unpublished NHLBI tabulation using NAMCS4 and NHAMCS5). • Incidence rates for PE and DVT increase expo- nentially with advancing age for both males and females.6,7 • VTE incidence varies by race/ethnicity.8–10 Black people are at greatest risk, followed by White, Hispanic, and Asian people. • Educational attainment has been inversely associ- ated with VTE risk.11 Lifetime Risk • The remaining lifetime risk of VTE at 45 years of age was 8.1% (95% CI, 7.1%–8.7%) overall, 11.5% in Black individuals, 10.9% in those with obesity, 17.1% in individuals with the FVL genetic mutation, and 18.2% in people with sickle cell trait or disease, according to data derived from nearly 20 000 participants of 2 US cohorts who were 45 to 99

Review the underlying epidemiology source

Evidence signal 2: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

24. VENOUS THROMBOEMBOLISM (DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM), CHRONIC VENOUS INSUFFICIENCY, PULMONARY HYPERTENSION See Table 24-1 and Charts 24-1 through 24-4 Click here to return to the Table of Contents Click here to return to the Abbreviations In this chapter, 2023 mortality data come from unpub­ lished NHLBI tabulations using NVSS1 and CDC WON­ DER.2 Hospital discharge data, from 2022, come from unpublished NHLBI tabulations using HCUP.3 Pulmonary Embolism ICD-10 I26. 2023, United States: Underlying cause mortality—8773. Any-mention mortality—46 561. 2022, United States: Hospital discharges—187 550 (principal diagnosis), 469 115 (all-listed diagnoses). Deep Vein Thrombosis ICD-10 I80.1, I80.2, I80.3, I80.9, I82.0, I82.1, I82.2, I82.3, I82.4, I82.5, I82.9. 2023, United States: Underlying cause mortality— 3265. Any-mention mortality—22 293. 2022, United States: Hospital discharges—70 175 (principal diagnosis), 712 950 (all-listed diagnoses). Venous Thromboembolism Incidence (See Charts 24-1 and 24-2) • VTE includes both PE and DVT. In 2022, there were an estimated ≈1 182 065 total VTE hospital discharges for all-listed diagnoses in the United States, including 469 115 cases of PE (Chart 24-1) and 712 950 cases of DVT (Chart 24-2).3 • A study of individuals in Oklahoma from 2012 to 2014 (whose ethnic profile is like that of the US population) observed an age-standardized inci­ dence of 2.47 (95% CI, 2.39–2.55), 1.47 (95%

Review the underlying epidemiology source

Evidence signal 3: Epidemiology and Genetics of Venous Thromboembolism and Chronic Venous Disease

20. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2017;117:219– 230. doi: 10.1160/TH16-08-0615 21. Lachance D, Garcia R. Atrial natriuretic factor release during volume expan- sion in the spontaneously hypertensive rat–effect of long-term hydrala- zine treatment. Clin Exp Hypertens A. 1991;13:235–259. doi: 10.3109/ 10641969109042061 22. Cohoon KP, Ashrani AA, Crusan DJ, Petterson TM, Bailey KR, Heit JA. Is infection an independent risk factor for venous thromboembolism? a popu- lation-based, case-control study. Am J Med. 2018;131:307.e2–316.e2. doi: 10.1016/j.amjmed.2017.09.015 23. Ahlehoff O, Wu JJ, Raunsø J, Kristensen SL, Khalid U, Kofoed K, Gislason G. Cutaneous lupus erythematosus and the risk of deep venous throm- bosis and pulmonary embolism: a Danish nationwide cohort study. Lupus. 2017;26:1435–1439. doi: 10.1177/0961203317716306 24. Aviña-Zubieta JA, Jansz M, Sayre EC, Choi HK. The risk of deep venous thrombosis and pulmonary embolism in primary sjögren syndrome: a general population-based study. J Rheumatol. 2017;44:1184–1189. doi: 10.3899/jrheum.160185 25. Folsom AR, Tang W, Roetker NS, Kshirsagar AV, Derebail VK, Lutsey PL, Naik R, Pankow JS, Grove ML, Basu S, et al. Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost. 2015;13:2–9. doi: 10.1111/jth.12787 26. Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler Thromb Vasc Biol.

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Venous Thrombosis, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Venous Thrombosis should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: NCC

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

The proposed mechanism anchor for this landscape is SLC12A3. Target selection does not imply that every Venous Thrombosis patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 2747 matched registered studies overall. The most recent records sampled for this report are:

• NCT07759635 — The Influence of Plan B® on Cardiovascular Health. (LEVOH); status: Recruiting; phase: Not Applicable; sponsor(s): McMaster University; enrollment: 40.
• NCT07749820 — Clinical Trial of Thrombectomy Systems; status: Recruiting; phase: Not Applicable; sponsor(s): BrosMed Medical Co., Ltd.; enrollment: 167.
• JPRN-UMIN000062482 — A study of deep vein thrombosis in total knee arthroplasty; status: 参加者募集終了‐試験継続中/No longer recruiting; phase: Not Applicable; sponsor(s): not stated; enrollment: 600.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Venous Thrombosis program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

The MCP search identified 2 directly matched recent transaction records. Representative records include:

• Fresenius to Expand Biopharma Portfolio with a New Licensing Agreement to commercialize a proposed Aflibercept biosimilar (2024-12-20). The record should be reviewed for structure, rights, stage and disclosed economics before it is used as a valuation comparable.
• Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market (2024-01-22). The record should be reviewed for structure, rights, stage and disclosed economics before it is used as a valuation comparable.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Venous Thrombosis.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Venous Thrombosis, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that SLC12A3 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Venous Thrombosis merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where SLC12A3 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Venous Thrombosis offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.